InspireMD (NSPR) Stock Price, News & Analysis

Company Overview

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

Key Stats

• Today's Range: $3.10 to $3.31
• 50-Day Range: $2.43 to $3.19
• 52-Week Range: $1.81 to $3.42
• Volume: 94,886 shs
• Average Volume: 43,217 shs
• Market Capitalization: $83.20 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.75
• Consensus Rating: Buy

InspireMD Stock Analysis - MarketRank™

InspireMD scored higher than 48% of companies evaluated by MarketBeat, and ranked 588th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

InspireMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

InspireMD has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for InspireMD are expected to grow in the coming year, from ($0.79) to ($0.73) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of InspireMD is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InspireMD is -4.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InspireMD has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NSPR.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InspireMD does not currently pay a dividend.

Dividend Growth

InspireMD does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NSPR.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.20

News Sentiment

InspireMD has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for InspireMD this week, compared to 1 article on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InspireMD insiders have not sold or bought any company stock.

Percentage Held by Insiders

29.72% of the stock of InspireMD is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

44.78% of the stock of InspireMD is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NSPR Stock Analysis - Frequently Asked Questions

How have NSPR shares performed this year?

InspireMD's stock was trading at $2.63 on January 1st, 2025. Since then, NSPR stock has increased by 21.3% and is now trading at $3.19.
View the best growth stocks for 2025 here.

How were InspireMD's earnings last quarter?

InspireMD, Inc. (NYSE:NSPR) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.04. The firm earned $1.81 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative trailing twelve-month return on equity of 69.42% and a negative net margin of 413.96%.

Who are InspireMD's major shareholders?

Top institutional shareholders of InspireMD include Rosalind Advisors Inc. (9.57%), Nantahala Capital Management LLC (6.42%), Parkman Healthcare Partners LLC (3.28%) and Millennium Management LLC (1.27%). Insiders that own company stock include Gary S Roubin and Paul Stuka.
View institutional ownership trends.

How do I buy shares of InspireMD?

Shares of NSPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InspireMD own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InspireMD investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NYSE:NSPR
• CUSIP: N/A
• CIK: 1433607
• Web: www.inspiremd.com
• Phone: 9728887766804
• Fax: N/A
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.75
• High Stock Price Target: $5.00
• Low Stock Price Target: $4.50
• Potential Upside/Downside: +48.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,920,000.00
• Net Margins: -413.96%
• Pretax Margin: -413.00%
• Return on Equity: -69.42%
• Return on Assets: -57.68%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.39
• Quick Ratio: 6.05

Sales & Book Value

• Annual Sales: $6.20 million
• Price / Sales: 13.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.83 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 26,080,000
• Free Float: 18,332,000
• Market Cap: $83.20 million
• Optionable: Optionable
• Beta: 1.00